{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-03-18",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "status": "Terminated",
      "city": "La Jolla",
      "state": "CA",
      "country": "United States",
      "classification": "Class III",
      "openfda": {
        "application_number": [
          "NDA200063"
        ],
        "brand_name": [
          "CONTRAVE"
        ],
        "generic_name": [
          "NALTREXONE HYDROCHLORIDE AND BUPROPION HYDROCHLORIDE"
        ],
        "manufacturer_name": [
          "Nalpropion Pharmaceuticals LLC"
        ],
        "product_ndc": [
          "51267-890"
        ],
        "product_type": [
          "HUMAN PRESCRIPTION DRUG"
        ],
        "route": [
          "ORAL"
        ],
        "substance_name": [
          "BUPROPION HYDROCHLORIDE",
          "NALTREXONE HYDROCHLORIDE"
        ],
        "rxcui": [
          "1551468",
          "1551474"
        ],
        "spl_id": [
          "8e7e5582-7a35-4ec7-85e7-b88a98d1bd23"
        ],
        "spl_set_id": [
          "485ff360-32c8-11df-928b-0002a5d5c51b"
        ],
        "package_ndc": [
          "51267-890-99",
          "51267-890-07"
        ],
        "is_original_packager": [
          true
        ],
        "upc": [
          "0351267890997"
        ],
        "unii": [
          "ZG7E5POY8O",
          "Z6375YW9SF"
        ]
      },
      "product_type": "Drugs",
      "event_id": "80801",
      "recalling_firm": "Orexigen Therapeutics, Inc.",
      "address_1": "3344 N Torrey Pines Ct Ste 200",
      "address_2": "",
      "postal_code": "92037-1024",
      "voluntary_mandated": "Voluntary: Firm initiated",
      "initial_firm_notification": "Letter",
      "distribution_pattern": "Nationwide in the USA",
      "recall_number": "D-1099-2018",
      "product_description": "Contrave (naltrexone HCl and bupropion HCl) Extended-Release Tablets, 8 mg/90 mg, 120-count bottle, Rx only, Distributed by Orexigen therapeutics, Inc., La Jolla, CA  92037, NDC 51267-890-99.",
      "product_quantity": "95,296 bottles",
      "reason_for_recall": "Defective Container: Customer complaints of punctures in the bottle.",
      "recall_initiation_date": "20180809",
      "center_classification_date": "20180816",
      "termination_date": "20191115",
      "report_date": "20180822",
      "code_info": "Lot #: ZCXM, Exp 01NOV2020; ZCXN, Exp 02NOV2020; ZCXP, Exp 09NOV2020; ZCXS, 10NOV2020; ZCXT, Exp 13NOV2020; and ZCXV, Exp 17NOV2020",
      "more_code_info": ""
    }
  ]
}